Safety and efficacy of azacitidine and ruxolitinib for acute myeloid leukemia with erythroid predominance or genomic abnormalities associated with activated JAK-STAT signaling pathway. - AZARUX for AEL study
100 Clinical Results associated with Novartis Egypt
0 Patents (Medical) associated with Novartis Egypt
100 Deals associated with Novartis Egypt
100 Translational Medicine associated with Novartis Egypt